首页> 外国专利> OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY)-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE

OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY)-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE

机译:包含碳酸酐酶抑制剂和S-(-)-1-(叔丁基丁醇)-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY)-2-PROPANOL的组合的眼科药物组合物在眼内压升高治疗中的典型应用

摘要

Although carbonic anhydrase inhibitors (C.A.I.) can be administered systemically by oral or intravenous routes, attempts to administer them topically have been ineffective and inactive in the treatment of intraocular hypertension. The alkali metal salts, especially the sodium and potassium salts, of salt-forming carbonic anhydrase inhibitors in combination with S-(-)-1- (tert-butylamino) -3-[(4-morpholino-1,2,5-thiadiazol -3-yl)oxy] -2-propanol or its racemic modification are now found to be remarkably effective in lowering intraocular pressure, even in normotensive hosts, but especially in those hosts having an elevated intraocular pressure.
机译:尽管碳酸酐酶抑制剂(C.A.I.)可以通过口服或静脉内途径全身给药,但是尝试局部给药它们在眼内高压的治疗中是无效且无活性的。与S-(-)-1-(叔丁基氨基)-3-[(4-吗啉代-1,2,5-)结合的成盐碳酸酐酶抑制剂的碱金属盐,尤其是钠盐和钾盐现已发现噻二唑-3-(基)氧基] -2-丙醇或其外消旋修饰在降低眼压方面非常有效,即使在血压正常的宿主中,尤其是在眼压升高的宿主中。

著录项

  • 公开/公告号IE49507B1

    专利类型

  • 公开/公告日1985-10-16

    原文格式PDF

  • 申请/专利权人 MERCK & CO. INC.;

    申请/专利号IE19800000207

  • 发明设计人

    申请日1980-02-01

  • 分类号A61K9/06;A61K31/41;

  • 国家 IE

  • 入库时间 2022-08-22 08:15:30

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号